{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal CardioCell",
            "NStudiesAvail": 430108,
            "NStudiesFound": 5,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 5,
            "FieldList": [
                  "MaximumAge",
                  "MinimumAge",
                  "NCTId",
                  "NCTIdAlias",
                  "OfficialTitle",
                  "OrgClass",
                  "OrgFullName",
                  "OrgStudyId",
                  "OrgStudyIdDomain",
                  "OrgStudyIdLink",
                  "OrgStudyIdType",
                  "OtherEventAssessmentType",
                  "OtherEventNotes",
                  "OtherEventOrganSystem",
                  "OtherEventSourceVocabulary"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "MaximumAge": [
                              "80 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT03404063"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Regeneration of Ischemic Damages in Cardiovascular System Using Wharton's Jelly as an Unlimited Source of Mesenchymal Stem Cells for Regenerative Medicine. Project of the National Centre for Research and Development (Poland) 'STRATEGMED II'. Cardiovascular Clinical Project to Evaluate the Regenerative Capacity of CardioCell in Patients With Acute Myocardial Infarction (AMI)."
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "John Paul II Hospital, Krakow"
                        ],
                        "OrgStudyId": [
                              "CardioCell evaluation in AMI"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 2,
                        "MaximumAge": [
                              "80 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT03418233"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Regeneration of Ischemic Damages in Cardiovascular System Using Wharton's Jelly as an Unlimited Source of Mesenchymal Stem Cells for Regenerative Medicine. Project of the National Centre for Research and Development (Poland) 'STRATEGMED II'. Randomized Clinical Trial to Evaluate the Regenerative Capacity of CardioCell in Patients With Chronic Ischaemic Heart Failure (CIHF)"
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "John Paul II Hospital, Krakow"
                        ],
                        "OrgStudyId": [
                              "CardioCell in CIHF"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 3,
                        "MaximumAge": [
                              "80 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT03423732"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Regeneration of Ischemic Damages in Cardiovascular System Using Wharton's Jelly as an Unlimited Source of Mesenchymal Stem Cells for Regenerative Medicine. Project of the National Centre for Research and Development (Poland) 'STRATEGMED II'. Cardiovascular Clinical Project to Evaluate the Regenerative Capacity of CardioCell in Patients With No-option Critical Limb Ischemia (N-O CLI)"
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "John Paul II Hospital, Krakow"
                        ],
                        "OrgStudyId": [
                              "CardioCell in N-O CLI"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 4,
                        "MaximumAge": [],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT02467387"
                        ],
                        "NCTIdAlias": [
                              "NCT02123706"
                        ],
                        "OfficialTitle": [
                              "A Phase IIa Randomized Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Ischemia-tolerant Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Non-ischemic Heart Failure"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "CardioCell LLC"
                        ],
                        "OrgStudyId": [
                              "STEM-104-M-CHF"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment"
                        ],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [
                              "General disorders",
                              "Investigations",
                              "Infections and infestations",
                              "Metabolism and nutrition disorders",
                              "Nervous system disorders",
                              "Respiratory, thoracic and mediastinal disorders",
                              "Musculoskeletal and connective tissue disorders"
                        ],
                        "OtherEventSourceVocabulary": [
                              "MedDRA (17.0)",
                              "MedDRA (17.0)",
                              "MedDRA (17.0)",
                              "MedDRA (17.0)",
                              "MedDRA (17.0)",
                              "MedDRA (17.0)",
                              "MedDRA (17.0)"
                        ]
                  },
                  {
                        "Rank": 5,
                        "MaximumAge": [
                              "85 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT01770613"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A PHASE IIa, DOUBLE-BLINDED, MULTI-CENTER, RANDOMIZED STUDY TO ASSESS THE SAFETY,TOLERABILITY, AND PRELIMINARY EFFICACY OF A SINGLE INTRAVENOUS DOSE OF ALLOGENEIC MESENCHYMAL BONE MARROW CELLS TO SUBJECTS WITH ST SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI)"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Stemedica Cell Technologies, Inc."
                        ],
                        "OrgStudyId": [
                              "STEM 103-M-STEMI"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  }
            ]
      }
}